Loading song details...
Arlene Siefker Radtke ESMO 2019 KEYNOTE 866 Phase III Trial In Bladder Cancer
No description available.
MP3 Download
Video Download
Related Songs
2:44
Arlene Siefker Radtke MD On The Management Of Treatment Emergent AEs Use FGFR Inhibitors
1:29
Arlene Siefker Radtke ASCO GU Highlights
1:19
Dr Siefker Radtke On Advancements In Small Cell Urothelial Cancer
1:18
Arlene Siefker Radtke MD Discusses Some Of The Antibody Drug Conjugates Currently In Development
4:42
Arlene Siefker Radtke MD Regarding The Development Of Erdafitinib In Bladder Cancer
0:55
Dr Siefker Radtke On FDA Approval Of Frontline Atezolizumab In Bladder Cancer
3:24
Arlene Siefker Radtke ESMO 2019 KEYNOTE 866 Phase III Trial In Bladder Cancer
0:53
Dr Siefker Radtke On FDA Approval Of Durvalumab In Bladder Cancer
0:45
Prof Siefker Radtke On The EV 103 Trial In Bladder Cancer
1:30
Arlene Siefker Radtke MD Shares The Role Of Selecting Mutations Vs Amplification For UC Treatment
0:53
Arlene Siefker Radtke MD Discusses Key Takeaways From The EV 301 Study In Urothelial Cancer
1:59
Arlene Siefker Radtke MD On How New Data Will Impact Treatment Of Neoadjuvant Bladder Cancer
1:47
Dr Siefker Radtke On PD L1 As A Biomarker In Bladder Cancer
0:38
Dr Siefker Radtke On FDA Approval Of Avelumab In Bladder Cancer
2:00
Arlene Siefker Radtke MD Regarding The EV 201 Cohort 2 Study Clinical Implications For Patients
1:28
Immune Checkpoint Inhibitors And Sitravatinib In Bladder Cancer
1:54
Dr Siefker Radtke On The Phase II Study Of Erdafitinib In Patients With Urothelial Carcinoma
2:20
Toxicity Management And Monitoring During Bladder Cancer Treatment
1:33
Arlene Siefker Radtke MD Speculates On The Role Of Antibody Drug Conjugates In Treatment UC
1:08